ASH 2023 | Venetoclax and intensive chemotherapy in NPM1-mutated AML: findings from the CAVEAT study
Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia, discusses the results of a post-hoc analysis of data from the CAVEAT study (ACTRN12616000445471) in which older patients (≥65 years of age) with NPM1-mutated acute myeloid leukemia (AML) were treated with venetoclax and intensive chemotherapy. This treatment regimen resulted in rapid and deep responses, as determined by NPM1(mut) measurable residual disease (MRD)-negativity. Interestingly, those patients who relapsed continued to exhibit low NPM1(mut) MRD status, suggesting that the therapy suppressed NPM1 mutations and relapse occurred as a result of other mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Astra Zeneca, AbbVie, Otsuka
Consultancy: AbbVie, Pfizer, Sumitomo Pharma Oncology
